Search Results - "Dobromilskaya, Irina"

Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer by AFTAB, Blake T, DOBROMILSKAYA, Irina, LIU, Jun O, RUDIN, Charles M

“…The antiangiogenic agent bevacizumab has been approved for the treatment of non-small cell lung cancer (NSCLC), although the survival benefit associated with…”
Get full text

Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer by POIRIER, J. T, DOBROMILSKAYA, Irina, MORIARTY, Whei F, PEACOCK, Craig D, HANN, Christine L, RUDIN, Charles M

“…We assessed the efficacy of Seneca Valley virus (SVV-001), a neuroendocrine cancer-selective oncolytic picornavirus, in primary heterotransplant mouse models…”
Get full text

Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer by GARDNER, Eric E, CONNIS, Nick, POIRIER, John T, COPE, Leslie, DOBROMILSKAYA, Irina, GALLIA, Gary L, RUDIN, Charles M, HANN, Christine L

“…Overexpression of the antiapoptotic protein Bcl-2 is observed in the majority of small cell lung cancer (SCLC) cases and is associated with resistance to…”
Get full text

Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer by HANN, Christine L, DANIEL, Vincent C, RUDIN, Charles M, SUGAR, Elizabeth A, DOBROMILSKAYA, Irina, MURPHY, Sara C, COPE, Leslie, XUE LIN, HIERMAN, Jared S, WILBURN, Daniel L, WATKINS, D. Neil

“…Bcl-2 is a central regulator of cell survival that is overexpressed in the majority of small cell lung cancers (SCLC) and contributes to both malignant…”
Get full text

ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer by Zinn, Rebekah L, Gardner, Eric E, Marchionni, Luigi, Murphy, Sara C, Dobromilskaya, Irina, Hann, Christine L, Rudin, Charles M

“…New therapies are critically needed to improve the outcome for patients with small cell lung cancer (SCLC). Insulin-like growth factor 1 receptor (IGF-1R)…”
Get full text

Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer by Vendetti, Frank P, Topper, Michael, Huang, Peng, Dobromilskaya, Irina, Easwaran, Hariharan, Wrangle, John, Baylin, Stephen B, Poirier, J T, Rudin, Charles M

“…Recent clinical data in lung cancer suggests that epigenetically targeted therapy may selectively enhance chemotherapeutic sensitivity. There have been few if…”
Get full text

Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer by Burns, Timothy F, Dobromilskaya, Irina, Murphy, Sara C, Gajula, Rajendra P, Thiyagarajan, Saravanan, Chatley, Sarah N H, Aziz, Khaled, Cho, Yoon-Jae, Tran, Phuoc T, Rudin, Charles M

“…A large fraction of non-small cell lung cancers (NSCLC) are dependent on defined oncogenic driver mutations. Although targeted agents exist for EGFR- and…”
Get full text

Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo by Osanyingbemi-Obidi, Joyce, Dobromilskaya, Irina, Illei, Peter B, Hann, Christine L, Rudin, Charles M

“…The Notch signaling pathway is a critical embryonic developmental regulatory pathway that has been implicated in oncogenesis. In non-small cell lung cancer…”
Get full text

Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer by Zinn, Rebekah L, Gardner, Eric E, Dobromilskaya, Irina, Murphy, Sara, Marchionni, Luigi, Hann, Christine L, Rudin, Charles M

“…New therapies are urgently needed for patients with small cell lung cancer (SCLC). Chemotherapy and targeted therapies, including the Bcl-2 inhibitor ABT-737,…”
Get full text

Abstract 3271: Inhibition of angiogenesis and tumor growth by itraconazole in primary xenograft models of human non-small cell lung cancer by Aftab, Blake T., Dobromilskaya, Irina, Hann, Christine L., Liu, Jun O., Rudin, Charles M.

“…Introduction: Lung cancer is the most common cause of cancer-related death in the US. Approximately 85 percent of cases are non-small cell lung cancer (NSCLC)…”
Get full text

Abstract 2954: TWIST1 is a critical mediator of KRAS mutant tumorigenesis in human non-small cell lung cancer by Burns, Timothy F., Dobromilskaya, Irina, Murphy, Sara C., Gajula, Rajendra P., Aziz, Khaled, Cho, Yoon-Jae, Tran, Phuoc T., Rudin, Charles M.

“…A large fraction of non-small cell lung cancers (NSCLC) have mutant KRAS, which is associated with poor response to current cytotoxic therapy and a poor…”
Get full text